Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series C+ financing round, securing over RMB 300 million (USD 41.3 million). This latest funding round was spearheaded by IDG Capital, with significant participation from Hankang Capital and Qianhai Ark Asset Management.
The capital raised in this round will be strategically allocated to bolster the company’s research and development efforts. Specifically, it will fund a Phase III clinical trial for Maxvax’s recombinant herpes zoster vaccine, as well as Phase I and II trials for its recombinant respiratory syncytial virus vaccine. This successful fundraising brings the total amount raised by Maxvax in Series C and C+ fundings to over RMB 600 million (USD 82.6 million) this year, providing the company with substantial financial resources to advance its vaccine pipeline.- Flcube.com
